Risk of cancer of unknown primary after hospitalization for autoimmune diseases

International Journal of Cancer

Volumn 137, Issue 12, 2015, Pages 2885-2895

  Hemminki, Kari ^a,b   Sundquist, Kristina ^a,c   Sundquist, Jan ^a,c   Ji, Jianguang ^a  

^a LUND UNIVERSITY   (Sweden)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmune diseases; cancer of unknown primary; national databases

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADDISON DISEASE; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BILIARY CIRRHOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER RISK; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMYOSITIS; PRIORITY JOURNAL; RISK ASSESSMENT; STANDARDIZED INCIDENCE RATIO; AUTOIMMUNE DISEASES; COHORT ANALYSIS; COMPLICATION; IMMUNOLOGY; INCIDENCE; NEOPLASMS, UNKNOWN PRIMARY; ONSET AGE; RISK FACTOR;

AGE OF ONSET; AUTOIMMUNE DISEASES; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; NEOPLASMS, UNKNOWN PRIMARY; RISK FACTORS;

EID: 84943666242     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29657     Document Type: Article

References (42)

1. Greco FA, Lennington WJ, Spigel DR, et al., Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst 2013; 105: 782-90
2. Hainsworth JD, Rubin MS, Spigel DR, et al., Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013; 31: 217-23
3. Greco F, Hainsworth J., Cancer of unknown primary site. In:, DeVita VJ, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology, vol. 9. Philadelphia: Lippincott, 2011. 2033-51
4. Hemminki K, Ji J, Sundquist J, et al., Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 2011; 29: 435-40
5. Pavlidis N, Pentheroudakis G., Cancer of unknown primary site. Lancet 2012; 379: 1428-35
6. Brustugun OT, Helland A., Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol 2014; 53: 134-7
7. Shu X, Sundquist K, Sundquist J, et al., Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev 2012; 21: 281-8
8. Urban D, Rao A, Bressel M, et al., Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer 2013; 109: 1318-24
9. Brewster DH, Lang J, Bhatti LA, et al., Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961-2010. Cancer Epidemiol 2014; 38: 227-34
10. Hemminki K, Bevier M, Hemminki A, et al., Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 2012; 23: 1854-63
11. Riihimaki M, Hemminki A, Sundquist K, et al., Time trends in survival from cancer of unknown primary: small steps forward. Eur J Cancer 2013; 49: 2403-10
12. Stella GM, Senetta R, Cassenti A, et al., Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med 2012; 10: 12
13. Schreiber RD, Old LJ, Smyth MJ., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70
14. Hemminki K, Bevier M, Sundquist J, et al., Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries? Ann Oncol 2012; 23: 2720-24
15. Oien K., Pathologic evaluation of unknown primary cancer. Semin Oncol 2009; 36: 8-37
16. Shu X, Liu H, Ji J, et al., Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights? Ann Oncol 2012; 23: 269-75
17. Forabosco P, Bouzigon E, Ng MY, et al., Meta-analysis of genome-wide linkage studies across autoimmune diseases. Eur J Hum Genet 2009; 17: 236-43
18. Zhernakova A, van Diemen CC, Wijmenga C., Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009; 10: 43-55
19. Dourmishev LA, Draganov PV., Paraneoplastic dermatological manifestation of gastrointestinal malignancies. World J Gastroenterol 2009; 15: 4372-9
20. Johnson AK., Repercussions of occult malignancy-an etiologic basis for rheumatic disease. Med Hypotheses 2013; 80: 447-51
21. Rothwell PM, Fowkes FG, Belch JF, et al., Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41
22. Cuzick J, Thorat MA, Bosetti C, et al., Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015; 26: 47-57
23. Ji J, Sundquist K, Sundquist J, et al., Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge Registry. Int J Cancer 2012; 131: 2085-93
24. Hemminki K, Bevier M, Sundquist J, et al., Site-specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries. Int J Cancer 2013; 132: 944-50
25. Breslow NE, Day NE., Statistical methods in cancer research. Volume II-the design and analysis of cohort studies. IARC Sci Publ 1987: 2: 1
26. Esteve J, Benhamou E, Raymond L., Statistical methods in cancer research, vol. 128. Lyon: IARC, 1994
27. Hemminki K, Chen B, Melander O, et al., Smoking and body-mass-index as risk factors for subtypes of cancer of unknown primary. Int J Cancer 2015; 136: 246-7
28. Kaaks R, Sookthai D, Hemminki K, et al., Risk factors for cancers of unknown primary site (CUP)-results from the prospective EPIC cohort. Int J Cancer 2014; 135: 2475-81
29. Hemminki k, Forsti A, Sundquist K, et al., Cancer of unknown primary is associated with diabetes. Eur J Cancer Prev, in press
30. Ludvigsson JF, Ludvigsson J, Ekbom A, et al., Celiac disease and risk of subsequent type 1 diabetes: a general population cohort study of children and adolescents. Diabetes Care 2006; 29: 2483-8
31. Smedby KE, Akerman M, Hildebrand H, et al., Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005; 54: 54-9
32. Knight A, Ekbom A, Brandt L, et al., Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001. J Rheumatol 2006; 33: 2060-3
33. Ludvigsson JF, Andersson E, Ekbom A, et al., External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450
34. Elfstrom P, Montgomery SM, Kampe O, et al., Risk of thyroid disease in individuals with celiac disease. J Clin Endocrinol Metab 2008; 93: 3915-21
35. Adeghate E, Schattner P, Dunn E., An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci 2006; 1084: 1-29
36. Hussain A, Claussen B, Ramachandran A, et al., Prevention of type 2 diabetes: a review. Diabetes Res Clin Pract 2007; 76: 317-26
37. Hemminki K, Liu X, Ji J, et al., Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol 2012; 127: 180-5
38. Hemminki K, Liu X, Ji J, et al., Autoimmune disease and subsequent digestive tract cancer by histology. Ann Oncol 2012; 23: 927-33
39. Hemminki K, Liu X, Ji J, et al., Effect of autoimmune diseases on risk and survival in histology-specific lung cancer. Eur Respir J 2012; 40: 1489-95
40. Liu X, Ji J, Forsti A, et al., Autoimmune disease and subsequent urological cancer. J Urol 2013; 189: 2262-8
41. Fallah M, Liu X, Ji J, et al., Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol 2014; 25: 2025-30
42. Landgren AM, Landgren O, Gridley G, et al., Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 2011; 117: 1163-71